US 12,421,314 B2
Binding molecules specific for fcγRIIA and uses thereof
Katherine Ann Vousden, Cambridgeshire (GB); Bo Chen, Frederick, MD (US); and Gary Patrick Sims, Potomac, MD (US)
Assigned to Horizon Therapeutics Ireland DAC, Dublin (IE)
Filed by Horizon Therapeutics Ireland DAC, Dublin 2 (IE)
Filed on Jul. 11, 2023, as Appl. No. 18/350,267.
Application 18/350,267 is a continuation of application No. 17/684,018, filed on Mar. 1, 2022, granted, now 11,746,153.
Application 17/684,018 is a continuation of application No. 16/097,573, granted, now 11,306,145, issued on Apr. 19, 2022, previously published as PCT/EP2017/060188, filed on Apr. 28, 2017.
Claims priority of provisional application 62/329,627, filed on Apr. 29, 2016.
Claims priority of provisional application 62/349,804, filed on Jun. 14, 2016.
Prior Publication US 2024/0287192 A1, Aug. 29, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 7/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/283 (2013.01) [A61P 7/00 (2018.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] 10 Claims
 
1. A pharmaceutical composition that comprises a binding molecule and a buffer, wherein the binding molecule comprises:
(i) a heavy chain variable (VH) region comprising a VH-complementarity determining region (CDR)1 comprising SEQ ID NO: 29, VH-CDR2 comprising SEQ ID NO: 19, and VH-CDR3 comprising SEQ ID NO: 30; and
(ii) a light chain variable (VL) region comprising a VL-CDR1 comprising SEQ ID NO: 22, VL-CDR2 comprising SEQ ID NO: 31, and VL-CDR3 comprising SEQ ID NO: 32.